Table 4 Clinicopathological characteristics of breast cancer patients of the validation cohort
Clinical variables | Validation cohort (n) | |
|---|---|---|
NW (6) (BMI < 24.9 kg/m2) | OW/Ob (12) (BMI ≥ 25 kg/m2) | |
Age, y | ||
 Median | 50 | 64 |
 Range | 34–73 | 46–83 |
 BMI Kg/m2, mean ± SD | 23 ± 1.8 | 30.6 ± 3 |
Histology, % | ||
 In situ ductal carcinoma | 0 | 0 |
 Invasive ductal carcinoma | 83 | 92 |
 Invasive lobular carcinoma | 0 | 8 |
Grading, % | ||
 Well differentiated (G1) | 17 | 0.8 |
 Moderately differentiated (G2) | 33 | 25 |
 Poor/undifferentiated (G3) | 33 | 58 |
 Unknown | 17 | 8.3 |
Menopausal status, % | ||
 Premenopausal | 50 | 17 |
 Postmenopausal | 50 | 83 |
Estrogen receptor status, % | ||
 Negative | 17 | 25 |
 Positive (> 1%) | 83 | 75 |
Progesterone receptor status, % | ||
 Negative | 33 | 33 |
 Positive (> 1%) | 67 | 67 |
HER2/Neu status, % | ||
 Negative | 50 | 92 |
 Positive | 33 | 8.3 |
Ki67, % | ||
  < 14 | 33 | 8.3 |
  ≥ 14 | 67 | 92 |